Sunday, November 25, 2018

Nanexa has completed a safety laboratory for the PharmaShell® process

[www.nanexa.se] Nanexa has now finalized a laboratory in Uppsala Sweden, which enables the company to work with cytostatics and other potent drugs. The laboratory has been built according to current occupational health and safety regulations and is adapted to produce materials for use in preclinical and clinical studies. Nanexa now has the capacity to produce clinical trials for, among other things, the company's product project NEX-18.
 

VD David Westberg presenterar bolaget (in Swedish)
 
Nanexa's CEO David Westberg comments: As we see it, this is a truly unique unit. It is highly likely that it is the first ALD (Atomic Layer Deposition) facility that is capable of coating potent drugs and is also qualifoed to manufacture under Good Manufacturing Practice (GMP) conditions, which is a necessity for materials to be used for clinical trials. 
 
It is also a significant strength that we have built up the capacity within the Company, which enables us to work flexibly with permanent staff and without being dependent on other companies' entries and priorities.